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association between the Symmetry and
proximal graft failure. My concern is in the
wider area of dissemination and adoption
of new technologies. Without statements
on data limitations, publication of biased
noncomparative data on any new technol-
ogy is potentially alarmist (or overoptimis-
tic), may prevent proper evaluation and
development, and may unnecessarily
hinder (or accelerate) uptake of new tech-
nologies, some of which could be poten-
tially beneficial (or harmful). Authors of
reports on new technologies should list
limitations and highlight any confounding
factors or alternative explanations for ad-
verse events (or benefits); otherwise read-
ers could be inadvertently misinformed.
Ani C. Anyanwu, FRCS
Cardiac Surgical Unit, Harefield Hospital
Middlesex, United Kingdom
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Reply to the Editor:
I thank Mr Anyanwu for his interesting
remarks.
I agree with the statement of Mr An-
yanwu concerning the use of the internal
thoracic arteries in coronary artery bypass
grafting. I used to follow the same strategy
and prefer extended utilization of the left
internal thoracic artery as a graft especially,
for the left anterior descending (LAD)
and/or diagonal branches. We accept it as
graft source irrespective of patient age, so
that in about 92% to 95% of the patients the
left internal thoracic artery is placed in the
LAD area, although the average patient age
is around 72 years old. I decided intention-
ally to make an exception to this strategy as
I wanted to gain intensive experience with
the new technology in creating the proxi-
mal vein graft anastomosis within a short
period of time, so that mostly no internal
thoracic arteries were used in the men-
tioned patient group unless the vein quality
was inadequate.
Although in this series the first use of
the anastomotic device took place on April
30, 2001, and the last one on October 22,
2001, of these 45 reported patients, 35 were
operated on in the relatively short period of
time from June 1 to July 5, 2001.
I agree that the calcified ascending aorta
implies the utilization of the pedicled inter-
nal thoracic arteries. However, I often
place many grafts in multimorbid octoge-
narians with more or less calcified ascend-
ing aortae, and I am forced to at least
partial use of vein grafts. I try then to find
the most suitable site for the proximal anas-
tomosis, regardless whether the given anas-
tomosis is hand-sewn in the conventional
way or performed by use of any anasto-
motic device. I have never faced results
like these until now. In very heavily calci-
fied ascending aortae, both techniques are
expected to fail; if at all possible the aorta
should be replaced.
For the same reason of gaining experi-
ence with off-pump techniques within this
period of time, accepted coronary patients
were primarily declared for off-pump pro-
cedure without any preselection (ie, regard-
less of coronary morphology and other rel-
evant factors).
I used to make the final decision to
proceed or not with the off-pump technique
at the very beginning of the surgery, mak-
ing it dependent on the feasibility of this
technique, so that many patients were
switched to on-pump without making any
effort to follow the off-pump strategy. I
converted to on-pump quite liberally for 2
reasons. First, I am generally not convinced
of the superiority of the off-pump tech-
niques; second, I often face an extremely
bad coronary morphology and/or bad ejec-
tion fraction. I mean the borderline cases in
whom the feasibility of coronary artery by-
pass grafting is generally problematic.
With those patients, we try to proceed with
the conventional bypass surgery before we
are forced to use any form of an end-stage
therapy (ie, heart transplantation, implanta-
tion of an assist device for recovery, for
bridging, or as definite surgery). Our heart
center is a leader in utilizing mechanical
circulatory support devices; we success-
fully follow this strategy in patients with
end-stage coronary artery disease for a long
time.
My article is a case report and not a
randomized study; as such, you will find no
comparison with any statistical signifi-
cance. However, the causality between the
utilized technology for creation of the
proximals and the reported complication is
in my opinion quite possible as these com-
plications are an exceptional “on the row”
phenomenon in my practice. I used to per-
form about 350 to 450 isolated coronary
artery bypass grafting procedures each
year; the operative capacity of the entire
heart center is about 5000 cardiac proce-
dures including approximately 3500 iso-
lated coronary artery bypass grafting pro-
cedures yearly. My colleagues and I have
never faced a similar experience. These
were the first graft occlusions or stenoses
that I had to deal with in many years.
I would like to use this opportunity to
report an additional case of severe stenosis
of the proximal vein graft anastomosis cre-
ated with ACS. A 65-year-old man with 1
sequential vein graft to LAD and diagonal
branch placed in off-pump technique using
the ACS developed de novo angina pecto-
ris 6 months after surgery. Angiography
revealed a severe stenosis of the proximal
anastomosis. Very impressive was the ret-
rograde filling of the graft until the ste-
nosed proximal anastomosis. The patient
underwent successful redo surgery; I could
not find any explanation for the event this
time, either. However, I do not claim to
deliver any evidence for or against the uti-
lization of the device. I have highlighted in
my article that the role of the device in the
genesis of the reported complications has
to be cleared.
Lech Hornik, MD, PhD
Department of Thoracic and
Cardiovascular Surgery
Heart Center North Rhine-Wesphalia
Bad Oeynhausen, Germany
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Pattern of lymphatic spread and
prognosis in pN1 non–small cell
lung cancer: What does it stand for?
To the Editor:
We read with great interest the report from
Marra and colleagues1 recently published
in the Journal, and we warmly congratulate
them on their excellent, accurate, and ex-
haustive analysis and report. They have
confirmed that within the pathologic N1
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(pN1) group of tumors involvement at the
intralobar level is substantially better prog-
nostically than that at the hilar level (as
well as single versus multiple nodes or
stations).
Because this strongly and comprehen-
sively supports the idea that it is correct to
stratify (classify) the pN1 cases according
to the level (intralobar best, hilar worst) in
addition to the number of involved lymph
nodes (one better, more than one worse) we
amicably invite Marra and colleagues to
clarify their position regarding the possible
use of such important information, espe-
cially regarding the opportunities to actu-
ally “stratify for optimization” in terms of
adjuvant and neoadjuvant treatment. In
fact, the discussion of their experience is
mainly focused on the evaluation of such
evidence in comparison to others’ similar
work. Regarding adjuvant treatment, we
have developed a timely consolidated ex-
perience in the adoption of postoperative
radiotherapy in completely resected non–
small cell lung cancers, even in the early
stage.2,3 Moreover we have directly dis-
cussed the Post Operative Radiotherapy
Trialists Group conclusions4 and strongly
support the evidence that modern radio-
therapy, accurately planned and adminis-
tered, can give good results with acceptable
side effects in this class of tumors.
From the report of Marra and col-
leagues,1 we have taken the idea that be-
cause for the best prognostic class pN1
cases any therapeutic effort aimed at the
local control could have significance, mod-
ern radiotherapy could certainly find its
place, especially at the investigational
level. For the worst prognostic class pN1
cases, we agree with Marra and colleagues1
that an attempt at systemic (rather than
local) control is justified. In the setting of
neoadjuvant treatment, we see the point of
view of the Marra and colleagues1 when
they note that it is “promising.” The core
fact in managing patients with N1 disease
in the clinical setting is that it is truly
difficult to obtain a substantially correct
diagnosis of true clinical N1 status. In their
very reported experience, in fact, Marra
and colleagues1 noted a limited (24.5%)
pathologic confirmation rate of clinical N1
assessment. Moreover, when a suspicion of
N1 involvement is present at the clinical
staging, this is rarely histologically or cy-
tologically assessable; thus an induction
treatment planned on the basis of the clin-
ical N1 status alone may still be considered
hazardous. In fact, the best that is currently
done in the ongoing phase III induction
trials for early stage non–small cell lung
cancers is to exclude, when N1 status is
suspected, the involvement of N2 stations
by cervical mediastinoscopy, leaving sub-
stantially uncovered the erroneously clini-
cally upstaged to N1 cases (true N0s). We
would be very grateful if Marra and col-
leagues could disclose and describe their
point of view regarding these issues.
Stefano Margaritora, MD
Alfredo Cesario, MD
Pierluigi Granone, MD
Division of General Thoracic Surgery
Catholic University
Rome, Italy
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Reply to the Editor:
We are glad to respond to the questions of
Margaritora and colleagues, as they come
from a thoracic surgical group with an es-
tablished experience in the multimodality
treatment of lung cancer.
The results of our study show that pN1
non–small cell lung cancer (NSCLC) could
not be considered an “early stage” disease,
because as many as 45% of patients at the
time of diagnosis and treatment had occult
disease beyond the boundaries of the lobe
of origin, if we consider that even a locore-
gional recurrence develops outside the
margins of “radical” surgical resection.
Another finding is that N1 NSCLC be-
haves heterogeneously, with two extremes:
a population of patients with hilar lymph
node metastases prognostically comparable
to “limited” N2 disease and, on the other
side, a more favorable subgroup of cases
with N1 disease by direct infiltration of
pulmonary lymph nodes. This difference
involves also the pattern of tumor relapse.
In fact, we have observed rates of cancer
recurrence of 41% at distant sites and of
12% locoregionally for the hilar N1 group
and of 24% and 17%, respectively, for the
N1 group by direct invasion. It is therefore
our opinion that the optimal treatment of all
these patients mandates multimodality ap-
proaches, which should be appropriately
investigated by means of randomized clin-
ical trials.
In the adjuvant setting, in all N1 sub-
groups the risk of distant metastases over-
whelms that of locoregional recurrence.
This evidence represents a rationale to use
systemic therapy (eg, chemotherapy) after
surgical resection, although the role and
effectiveness of adjuvant chemotherapy in
early stage NSCLC are still controver-
sial.1,2 Radiotherapy seems to be less man-
datory, because adequate surgery is able to
achieve long-term local control in as many
as 85% of patients and chemotherapy may
also contribute to reduce locoregional fail-
ures. Nevertheless, the cited phase III study
on patients with N0 NSCLC suggests that
modern radiation therapy improves local
control with an acceptable toxicity.3,4 Fur-
ther randomized trials are needed to define
the role of radiotherapy in N1 NSCLC.
Interesting data could be obtained from the
forthcoming publication of the results of
the International Adjuvant Lung Cancer
Trial (EORTC Trial CT0142), which in
stages I to IIIA NSCLC compares different
adjuvant chemotherapy regimens (cisplatin
plus VP16 or cisplatin plus vinca alkaloids)
against control, with radiotherapy being
optional.
In the neoadjuvant setting, preopera-
tively scheduled chemotherapy, alone or in
combination with radiotherapy, provides
survival advantages in locoregionally ad-
vanced NSCLC, as shown by many clinical
trials.5-7 Phase II studies of patients with
early-stage NSCLC treated with induction
chemotherapy have had encouraging re-
sults, but randomized trials are needed to
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